bromocriptine has been researched along with Obesity in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (16.67) | 18.7374 |
| 1990's | 13 (27.08) | 18.2507 |
| 2000's | 15 (31.25) | 29.6817 |
| 2010's | 8 (16.67) | 24.3611 |
| 2020's | 4 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Auriemma, RS; Colao, A; Graziadio, C; Pirchio, R; Pivonello, R | 1 |
| Aslanoglou, D; Benner, V; Farino, ZJ; Freyberg, Z; Lopez-Valencia, M; McCarthy, MJ; Osborn, O; Wei, H; Zapata, RC | 1 |
| Bloomgarden, Z | 1 |
| Barra, C; Conde, SV; Costa, A; Gasparini, P; Marques, D; Matafome, P; Melo, BF; Rodrigues, T; Rosendo-Silva, D; Sacramento, JF; Seiça, R; Tavares, G | 1 |
| Boaventura, G; Casimiro-Lopes, G; Lisboa, PC; Moura, EG; Oliveira, E; Pazos-Moura, CC | 1 |
| Carvalho, JC; Conceição, EP; de Oliveira, E; Lima, NS; Lisboa, PC; Moura, EG; Nogueira-Neto, JF; Peixoto-Silva, N | 1 |
| Carvalho, JC; de Oliveira, E; Lisboa, PC; Moura, EG; Nobre, JL; Peixoto-Silva, N; Pinheiro, CR; Quitete, FT; Santos-Silva, AP | 1 |
| Frölich, M; Kok, P; Meinders, AE; Pijl, H; Roelfsema, F; van Pelt, J | 3 |
| Aja, S; Cheskin, LJ; Contoreggi, C; Davis, LM; Hope, B; McCullough, K; Michaelides, M; Moran, TH; Pei, Z; Thanos, PK; Volkow, ND; Wang, GJ; Watkins, PA | 1 |
| Bonomo, IT; de Moura, EG; de Oliveira, E; Lisboa, PC; Nogueira-Neto, JF; Passos, MC; Reis, AM; Trevenzoli, IH | 1 |
| Bonomo, IT; de Oliveira, E; Lima, NS; Lisboa, PC; Moura, EG; Passos, MC; Pires, L; Reis, AM | 1 |
| Barbosa, FR; Domingues, RC; dos Santos Silva, CM; Fontes, R; Gadelha, MR; Lima, GA; Warszawski, L | 1 |
| Anderson, BJ; Bray, GA; Cho, J; Kim, R; Michaelides, M; Primeaux, SD; Robinson, JK; Thanos, PK; Volkow, ND; Wang, GJ | 1 |
| Bray, G; Cho, J; Kim, R; Michaelides, M; Primeaux, S; Thanos, PK; Volkow, ND; Wang, GJ | 1 |
| de Leeuw van Weenen, JE; Parlevliet, ET; Pijl, H; Romijn, JA; Schröder-van der Elst, JP; van den Berg, SA; Willems van Dijk, K | 1 |
| Amini, M; Aminorroaya, A; Haghighi, S; Janghorbani, M; Ramezani, M | 1 |
| Cheskin, LJ; Contoreggi, C; Davis, LM; McCullough, K; Moran, TH; Pei, Z; Trush, MA; Watkins, PA | 1 |
| Frölich, M; Kok, P; Meinders, AE; Pijl, H; Roelfsema, F; Stokkel, MP; van Pelt, J | 1 |
| Cerman, J; Golda, V; Petr, R; Suba, P; Votruba, M | 1 |
| Cincotta, AH; Meier, AH | 2 |
| Roush, W | 1 |
| Cvak, L; Golda, V | 1 |
| Barberis, A; Camanni, F; Ciccarelli, E; Ghigo, E; Grottoli, S; Maccario, M; Oleandri, SE; Procopio, M | 1 |
| Cincotta, AH; Scislowski, PW; Tozzo, E | 1 |
| Chen, YD; Cincotta, AH; Jones, CN; Kamath, V; Reaven, GM; Varasteh, BB; Yip, JC | 1 |
| Cincotta, AH; Luo, S; Meier, AH | 1 |
| Cincotta, AH; Liang, Y; Luo, S | 1 |
| Cincotta, AH; Phaneuf, S; Prevelige, R; Scislowski, PW; Tozzo, E; Zhang, Y | 1 |
| Cincotta, AH; Kraszewski, KZ | 1 |
| Cincotta, AH; Luo, J; Luo, S | 1 |
| Iwamoto, Y; Kawahara, R; Wasada, T | 1 |
| Reaven, GM | 1 |
| Cincotta, AH; DeFronzo, RA; Iozzo, P; Kumar, V; Lancaster, JL; Mahankali, A; Matsuda, M; Miyazaki, Y; Ohashi, S; Pijl, H; Pipek, R | 1 |
| Barzaghi, ME; Beck-Peccoz, P; Bortolani, E; Corti, D; Forloni, F; Giovilli, M; Pecis, C; Preziosi, A | 1 |
| Casanueva, F; Dieguez, C; Doknic, M; Medic-Stojanoska, M; Pekic, S; Popovic, V; Zarkovic, M | 1 |
| Craig, A; Harrower, AD; Nairn, IM; Strong, JA; Walton, HJ; Yap, PL | 1 |
| Franks, S; Jacobs, HS; Jequier, AM; Murray, MA; Nabarro, JD; Steele, SJ | 1 |
| Manusharova, RA | 1 |
| Cincotta, AH; Lovell, WC; Meier, AH | 1 |
| Cincotta, AH; Meier, AH; Schiller, BC | 1 |
| Tiwary, CM | 1 |
| Burema, J; Deurenberg, P; Rokebrand, P; Rookus, MA | 1 |
| Vaitukaitis, JL | 1 |
| Adams, J; Franks, S; Mason, H; Polson, D | 1 |
| Blom, HL; Larsson, LO | 1 |
2 review(s) available for bromocriptine and Obesity
| Article | Year |
|---|---|
Metabolic effects of prolactin.
Topics: Bromocriptine; Cabergoline; Dopamine; Dopamine Agonists; Glucose; Humans; Hyperprolactinemia; Lipids; Male; Metabolic Syndrome; Obesity; Prolactin; Receptors, Dopamine; Receptors, Prolactin; Testosterone; Weight Gain | 2022 |
Ovulatory disorders in women with polycystic ovary syndrome.
Topics: Androgens; Anovulation; Bromocriptine; Chorionic Gonadotropin; Clomiphene; Diagnosis, Differential; Estrogens; Female; Follicle Stimulating Hormone; Glucocorticoids; Gonadotropin-Releasing Hormone; Gonadotropins, Pituitary; Hirsutism; Humans; Hyperprolactinemia; Infertility, Female; Menotropins; Menstruation Disturbances; Obesity; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Ultrasonography | 1985 |
10 trial(s) available for bromocriptine and Obesity
| Article | Year |
|---|---|
Short-term treatment with bromocriptine improves impaired circadian growth hormone secretion in obese premenopausal women.
Topics: Adult; Bromocriptine; Chronobiology Disorders; Circadian Rhythm; Cross-Over Studies; Dopamine Agonists; Female; Human Growth Hormone; Humans; Insulin; Leptin; Middle Aged; Obesity; Placebos; Premenopause; Time Factors | 2008 |
Does bromocriptine improve glycemic control of obese type-2 diabetics?
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Double-Blind Method; Drug Synergism; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Placebos | 2004 |
Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women.
Topics: Adult; Blood Glucose; Bromocriptine; Calorimetry, Indirect; Circadian Rhythm; Cross-Over Studies; Dopamine Agonists; Eating; Energy Metabolism; Fatty Acids, Nonesterified; Female; Humans; Insulin; Insulin Resistance; Metabolic Syndrome; Middle Aged; Nitrogen; Obesity; Oxygen Consumption; Prolactin; Receptors, Dopamine D2; Urea | 2006 |
Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects.
Topics: Adipose Tissue; Blood Glucose; Body Mass Index; Body Weight; Bromocriptine; Diet, Reducing; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Male; Middle Aged; Obesity; Placebos; Time Factors; Weight Loss | 1996 |
Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity.
Topics: Adolescent; Adult; Arginine; Blood Glucose; Bromocriptine; Dopamine Agonists; Hormone Antagonists; Human Growth Hormone; Humans; Insulin; Insulin Secretion; Middle Aged; Obesity; Prolactin; Secretory Rate | 1996 |
Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Bromocriptine; Cholesterol; Dopamine Agonists; Fasting; Fatty Acids, Nonesterified; Female; Humans; Hyperinsulinism; Insulin; Lipid Metabolism; Lipids; Lipoproteins; Middle Aged; Obesity; Postprandial Period; Prolactin; Triglycerides | 1997 |
Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Blood Glucose; Body Mass Index; Body Weight; Bromocriptine; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Female; Glucose Tolerance Test; Glycated Hemoglobin; Hormone Antagonists; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Placebos; Time Factors; Viscera | 2000 |
Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
Topics: Adolescent; Adult; Basal Metabolism; Body Weight; Bromocriptine; Dopamine; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Leptin; Male; Middle Aged; Obesity; Pituitary Neoplasms; Prolactin; Prolactinoma | 2002 |
Incidence and significance of hyperprolactinaemia in women with amenorrhea.
Topics: Adult; Amenorrhea; Anorexia Nervosa; Bromocriptine; Clinical Trials as Topic; Contraceptives, Oral; Female; Galactorrhea; Gonadotropins; Humans; Hypophysectomy; Obesity; Ovarian Diseases; Pituitary Neoplasms; Pregnancy; Prolactin | 1975 |
Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics.
Topics: Body Composition; Bromocriptine; Diabetes Mellitus, Type 2; Fats; Female; Humans; Hyperglycemia; Male; Menopause; Obesity; Skinfold Thickness | 1992 |
36 other study(ies) available for bromocriptine and Obesity
| Article | Year |
|---|---|
Dopamine D
Topics: Animals; Blood Glucose; Bromocriptine; Circadian Rhythm; Diabetes Mellitus, Type 2; Dopamine; Dopamine Agonists; Female; Glucose; Insulin; Insulin-Secreting Cells; Levodopa; Mice; Mice, Inbred C57BL; Obesity; Receptors, Dopamine D2; Sulpiride; Weight Gain | 2020 |
Various and sundry recent publications.
Topics: Bromocriptine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Heart Rate; Humans; Insulin Resistance; Obesity | 2021 |
Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes.
Topics: Adult; Aged; Animals; Bariatric Surgery; Bromocriptine; Cohort Studies; Diabetes Mellitus, Type 2; Disease Models, Animal; Dopamine; Dopamine Agonists; Female; Humans; Insulin Resistance; Intra-Abdominal Fat; Lipid Metabolism; Male; Metabolic Networks and Pathways; Metabolome; Metabolomics; Middle Aged; Obesity; Rats; Receptors, Dopamine D2 | 2021 |
Effects of running wheel training on adult obese rats programmed by maternal prolactin inhibition.
Topics: Animals; Bromocriptine; Female; Glycogen; L-Lactate Dehydrogenase; Lactation; Lipid Metabolism; Male; Metabolic Syndrome; Mothers; Motor Activity; Muscles; Obesity; Physical Conditioning, Animal; Prolactin; Rats; Rats, Wistar; Weaning | 2013 |
Does bromocriptine play a role in decreasing oxidative stress for early weaned programmed obesity?
Topics: Adiposity; Animals; Bromocriptine; Dyslipidemias; Female; Glucose; Injections, Intraperitoneal; Insulin Resistance; Intra-Abdominal Fat; Liver; Liver Diseases; Male; Obesity; Oxidation-Reduction; Oxidative Stress; Prolactin; Rats; Rats, Wistar; Time Factors; Weaning | 2014 |
Bromocriptine treatment at the end of lactation prevents hyperphagia, higher visceral fat and liver triglycerides in early-weaned rats at adulthood.
Topics: Animals; Bromocriptine; Female; Glucose; Homeostasis; Hyperphagia; Intra-Abdominal Fat; Lactation; Leptin; Liver; Male; Obesity; Rats; Rats, Wistar; Triglycerides; Weaning | 2017 |
Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity.
Topics: Adiposity; Animals; Bromocriptine; Diet; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Eating; Hyperphagia; Male; Motor Activity; Obesity; Rats; Rats, Zucker; Receptors, Dopamine D2; Receptors, Leptin | 2009 |
Bromocriptine reduces augmented thyrotropin secretion in obese premenopausal women.
Topics: Bromocriptine; Circadian Rhythm; Cross-Over Studies; Energy Intake; Female; Half-Life; Humans; Leptin; Obesity; Placebos; Premenopause; Pulse; Thyrotropin | 2009 |
Maternal prolactin inhibition during lactation programs for metabolic syndrome in adult progeny.
Topics: Adult Children; Animals; Blood Glucose; Body Composition; Bromocriptine; Female; Hormone Antagonists; Humans; Lactation; Metabolic Diseases; Obesity; Prolactin; Rats; Rats, Wistar; Weaning | 2009 |
Prolactin inhibition at mid-lactation influences adiposity and thyroid function in adult rats.
Topics: Adiposity; Aging; Animals; Bromocriptine; Feeding Behavior; Female; Hypothyroidism; Lactation; Leptin; Malnutrition; Milk; Obesity; Prolactin; Rats; Rats, Wistar; Thyroid Gland; Weight Gain | 2010 |
BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
Topics: Adult; Aftercare; Aged; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Bromocriptine; Cabergoline; Cholesterol, HDL; Cholesterol, LDL; Dopamine Agonists; Ergolines; Female; Humans; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metabolome; Middle Aged; Obesity; Prevalence; Prolactinoma; Waist Circumference; Weight Gain; Young Adult | 2011 |
Obesity-resistant S5B rats showed greater cocaine conditioned place preference than the obesity-prone OM rats.
Topics: Analysis of Variance; Animals; Association Learning; Bromocriptine; Cocaine; Conditioning, Psychological; Dopamine Agonists; Dopamine Uptake Inhibitors; Male; Obesity; Rats; Receptors, Dopamine D2 | 2010 |
Bromocriptine increased operant responding for high fat food but decreased chow intake in both obesity-prone and resistant rats.
Topics: Animals; Bromocriptine; Conditioning, Operant; Dietary Fats; Dose-Response Relationship, Drug; Eating; Male; Obesity; Rats; Rats, Inbred Strains; Reinforcement Schedule; Self Administration; Species Specificity | 2011 |
Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice.
Topics: Animals; Behavior, Animal; Body Weight; Bromocriptine; Dietary Fats; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Energy Metabolism; Haloperidol; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Motor Activity; Obesity; Phenotype; Random Allocation; Receptors, Dopamine D2; Synaptic Transmission | 2011 |
Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese women.
Topics: Adult; Blood Glucose; Bromocriptine; Circadian Rhythm; Cross-Over Studies; Dopamine Agonists; Fatty Acids, Nonesterified; Female; Humans; Insulin; Leptin; Middle Aged; Norepinephrine; Obesity; Premenopause; Prospective Studies; Receptors, Dopamine D2; Receptors, Leptin; Triglycerides | 2006 |
Bromocriptine reduces steatosis in obese rodent models.
Topics: Animals; Blood Glucose; Body Composition; Bromocriptine; Disease Models, Animal; Dopamine Agonists; Eating; Fatty Liver; Liver; Locomotion; Male; Obesity; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Zucker; Superoxide Dismutase; Triglycerides | 2006 |
Studies in behaviour, brain and plasma biochemistry in normotensive, genetically hypertensive nonobese and/or genetically hypertensive obese rats: effect of bromocriptine.
Topics: Animals; Brain; Bromocriptine; Exploratory Behavior; Female; Hypertension; Male; Obesity; Rats | 1980 |
Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus).
Topics: Animals; Blood Glucose; Bromocriptine; Circadian Rhythm; Cricetinae; Disease Models, Animal; Energy Metabolism; Fatty Acids, Nonesterified; Female; Glucose; Hormone Antagonists; Hyperinsulinism; Insulin; Insulin Resistance; Lipolysis; Liver; Mesocricetus; Obesity; Oxidation-Reduction; Seasons | 1995 |
Can "resetting" hormonal rhythms treat illness?
Topics: Animals; Bromocriptine; Circadian Rhythm; Clinical Trials, Phase III as Topic; Darkness; Diabetes Mellitus, Type 2; Humans; Light; Melatonin; Obesity; Prolactin | 1995 |
Terguride but not bromocriptine alleviated glucose tolerance abnormalities and hyperlipidaemia in obese and lean genetically hypertensive Koletsky rats.
Topics: Animals; Blood Pressure; Body Weight; Bromocriptine; Disease Models, Animal; Female; Glucose Intolerance; Hyperlipidemias; Hypertension; Insulin; Lipids; Lisuride; Male; Obesity; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rats, Wistar; Sex Factors | 1994 |
Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Body Composition; Body Weight; Bromocriptine; Dopamine Agonists; Feeding Behavior; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Receptors, Dopamine D1 | 1997 |
Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters.
Topics: Adipose Tissue; Animals; Biogenic Monoamines; Body Composition; Bromocriptine; Chromatography, High Pressure Liquid; Circadian Rhythm; Cricetinae; Dopamine; Glucose Intolerance; Homovanillic Acid; Hydroxyindoleacetic Acid; Hypothalamus, Middle; Insulin Resistance; Male; Methoxyhydroxyphenylglycol; Microdialysis; Obesity; Serotonin | 1998 |
Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters.
Topics: Animals; Blood Glucose; Bromocriptine; Cricetinae; Glucose Clamp Technique; Glucose Intolerance; Injections, Intraventricular; Insulin; Insulin Resistance; Male; Mesocricetus; Obesity; Photoperiod; Weight Gain | 1999 |
Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adipose Tissue; Animals; Blood Glucose; Bromocriptine; Diabetes Mellitus; Dopamine Agonists; Drug Synergism; Eating; Energy Metabolism; Fatty Acids, Nonesterified; Female; Gluconeogenesis; Lipids; Lipolysis; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Weight Loss | 1999 |
Increased responsiveness of ventromedial hypothalamic neurons to norepinephrine in obese versus lean mice: relation to the metabolic syndrome.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Bromocriptine; Dopamine Agonists; Electrophysiology; Female; Glutamic Acid; Hyperglycemia; Iontophoresis; Mice; Mice, Inbred C57BL; Mice, Obese; Neurons; Norepinephrine; Obesity; Receptors, Dopamine D1; Receptors, Dopamine D2; Syndrome; Ventromedial Hypothalamic Nucleus | 2000 |
Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster.
Topics: Animals; Biogenic Monoamines; Blood Glucose; Body Weight; Bromocriptine; Circadian Rhythm; Cricetinae; Dopamine; Dopamine Agonists; Fatty Acids, Nonesterified; Glucose Intolerance; Glucose Tolerance Test; Hormones; Hypoglycemic Agents; Insulin Resistance; Male; Mesocricetus; Obesity; Serotonin; Suprachiasmatic Nucleus | 2000 |
Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients.
Topics: Abdomen; Adipose Tissue; Blood Glucose; Bromocriptine; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dopamine Agonists; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Male; Middle Aged; Obesity; Prolactin; Skin | 2000 |
Are the results really different?
Topics: Blood Glucose; Bromocriptine; Cholesterol, HDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dopamine Agonists; Female; Humans; Insulin Resistance; Obesity | 2000 |
Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male.
Topics: Biopsy; Breast Neoplasms, Male; Bromocriptine; Carcinoma, Ductal, Breast; Estradiol; Hormone Antagonists; Humans; Hypogonadism; Male; Mammography; Mastectomy; Middle Aged; Neoplasms, Multiple Primary; Obesity; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone; Tomography, X-Ray Computed | 2001 |
Growth hormone, insulin, and prolactin secretion in anorexia nervosa and obesity during bromocriptine treatment.
Topics: Adolescent; Adult; Anorexia Nervosa; Bromocriptine; Ergolines; Female; Glucose Tolerance Test; Growth Hormone; Humans; Insulin; Insulin Secretion; Obesity; Prolactin | 1977 |
[The treatment of the climacteric syndrome in women suffering from Itsenko-Cushing disease and primary obesity].
Topics: Adrenal Glands; Bromocriptine; Climacteric; Combined Modality Therapy; Cushing Syndrome; Female; Humans; Hypothalamo-Hypophyseal System; Middle Aged; Norethindrone; Obesity; Ovary; Syndrome | 1992 |
Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Bromocriptine; Cricetinae; Female; Glucose Tolerance Test; Hyperglycemia; Hyperinsulinism; Insulin Resistance; Mesocricetus; Obesity; Seasons | 1991 |
Prolactinoma in an adolescent girl: unusual response to bromocriptine therapy.
Topics: Adolescent; Bromocriptine; Female; Humans; Menstruation; Obesity; Pituitary Neoplasms; Prolactin; Prolactinoma | 1989 |
The effect of pregnancy on the body mass index 9 months postpartum in 49 women.
Topics: Aging; Body Height; Body Weight; Bromocriptine; Female; Humans; Lactation; Obesity; Postpartum Period; Pregnancy; Regression Analysis; Smoking; Time Factors | 1987 |
Polycystic ovary syndrome.
Topics: Androgens; Bromocriptine; Dexamethasone; Female; Genes, Dominant; Hirsutism; Humans; Hypothalamo-Hypophyseal System; Infertility, Female; Obesity; Polycystic Ovary Syndrome | 1986 |
[Unexpected positive effect of bromocriptine on obesity and the use of psychopharmaceuticals].
Topics: Adult; Bromocriptine; Edema; Female; Humans; Mental Disorders; Obesity; Psychotropic Drugs; Substance-Related Disorders | 1985 |